Insulet stock has fallen sharply over the past year, yet on current market multiples it still screens as expensive. This leaves investors weighing a weak share price record against valuation checks that do not flag a clear bargain.

• Insulet has declined 44.7% over the last 12 months, which means the stock has given back a large amount of value despite more recent short term gains.
• Product quality issues and related recalls around the Omnipod franchise can weigh on sentiment, while ongoing international expansion of Omnipod 5 may support expectations for future revenue.
• With a value score of 2 out of 6, Insulet currently looks more like a stock the broader checks see as leaning expensive than an obvious value opportunity.

The stock's next move may depend on whether current expectations for Insulet's growth and legal risks justify paying what still looks like a premium valuation after such a steep pullback.

Has Insulet Run Too Far on Earnings?

The P/E ratio suits Insulet because earnings are a key focus for many investors in established medical equipment stocks. Insulet trades on a P/E of 36.4x, slightly above the peer average of 35.1x and well ahead of the wider Medical Equipment industry on 26.1x. That already places the stock at a premium to many listed healthcare equipment peers, even after its share price setback.

A tailored fair P/E ratio for Insulet, which blends its sector, size and risk profile, sits lower at 32.0x. Compared with the current 36.4x, this suggests the market is still asking investors to pay extra versus what these checks flag as a more grounded multiple. Despite the recent Class I recall for Omnipod pods and associated lawsuits, the market-multiple workup indicates Insulet stock continues to carry a valuation premium that is not fully explained by these benchmarks.

On this P/E framework, Insulet stock screens as overvalued rather than a clear bargain.

The Insulet Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Insulet's valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, all in one place on the Community page. Each narrative links its number to a clear view on how Insulet's growth, profitability and risks might evolve, giving you something concrete to revisit as new information arrives.

One of the top community narratives on Insulet: 50% undervalued

"This narrative explores a more optimistic perspective on Insulet compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts..."

Do you think there's more to the story for Insulet? Head over to our Community to see what others are saying!

The Bottom Line

For Insulet, the market-multiple work points to an overvalued stock, with the current P/E still sitting above both a tailored fair multiple and wider medical equipment peers. That leaves limited room for error if growth, margins or legal outcomes fall short of what the current valuation implies. The low value score reinforces that broader checks do not yet frame Insulet as a valuation-led opportunity. The crux for investors is whether Omnipod growth and associated profitability can progress in a way that makes today’s premium look earned rather than exposed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.